The tweet was deleted by the author.
But we saved everything 🙂.
NovoCure Ltd secured approval from Japan’s Ministry of Health, Labour and Welfare for reimbursement of its treatment for non-small cell lung cancer under the country’s National Health Insurance coverage.
This milestone enables increased patient access to the therapy in the Japanese market and marks a significant expansion of NovoCure Ltd’s global reach. Further details were shared in the company’s official press release.